
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. is projected to have significant upside potential based on its valuation, which balances high risks with substantial opportunities in the medical diagnostics market. The company's advancements with Medicare suggest the potential for positive coverage announcements, which could enhance its market position and drive revenue growth. Additionally, EsoGuard’s first mover advantage and superior testing capabilities position Lucid as an appealing acquisition target, further supporting a positive outlook for the company’s stock.
Bears say
Lucid Diagnostics Inc reported a pro forma net loss of $9.9 million, resulting in an earnings per share (EPS) of $(0.10), slightly worse than internal estimates of $(0.09) and consensus expectations of $(0.12). Furthermore, the volume of EsoGuard tests processed decreased significantly to 2,756 in Q2, down from prior quarterly figures, indicating a troubling decline in demand for the company's primary product. The company also faces numerous risks, including liquidity concerns, product efficacy, regulatory approval, reimbursement challenges, and heightened competition, all contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares